Oculis Holding shares are trading higher after the company announces that the first patient has been randomized in the PREDICT-1 genotype-based registrational trial in dry eye disease.

Benzinga Newsdesk www.benzinga.com Positive 94.7%

Neg 0% Neu 0% Pos 94.7%

Comments

No comments yet. Be the first!